Related Experiment Video

Updated: Oct 24, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs

M Bentires-Alj1, A C Hellin, M Ameyar

  • 1Laboratory of Medical Chemistry/Medical Oncology, University of Liège, Belgium.

Cancer Research
|February 24, 1999
PubMed

Insights

Nuclear factor kappaB (NF-kappaB) activation can protect cells from apoptosis. Inhibiting NF-kappaB did not alter cancer cell survival when treated with chemotherapy drugs in this study.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Nuclear factor kappaB (NF-kappaB) activation is known to confer resistance to apoptosis induced by various stimuli, including chemotherapy.
  • Understanding the role of NF-kappaB in chemoresistance is crucial for developing more effective cancer therapies.

Purpose of the Study:

  • To investigate the impact of inhibiting NF-kappaB on the efficacy of antineoplastic agents.
  • To determine if blocking NF-kappaB signaling enhances cancer cell sensitivity to chemotherapy.

Main Methods:

  • Utilized multiple human cancer cell lines (HPB, HCT116, MCF7, OVCAR-3) engineered to stably express a dominant-negative inhibitor of IkappaBalpha.
  • Assessed NF-kappaB activation levels following treatment with tumor necrosis factor-alpha and various chemotherapeutic agents.
  • Compared the survival rates of parental cells versus cells with inhibited NF-kappaB signaling.

Main Results:

  • Stable inhibition of NF-kappaB signaling was confirmed in engineered cell lines.
  • NF-kappaB inhibition did not significantly alter the survival of cancer cells when exposed to cytotoxic drugs.
  • The response to chemotherapeutic agents remained unchanged despite the suppression of NF-kappaB activation.

Conclusions:

  • In the tested cancer cell lines, stable inhibition of the NF-kappaB pathway does not enhance the effectiveness of conventional cytotoxic chemotherapy.
  • Targeting NF-kappaB alone may not be a sufficient strategy to overcome chemoresistance in these specific cancer models.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...